Tag Archives: deflazacort

March, 2017

February, 2017

June, 2016

  • 15 June

    Marathon Seeks FDA Approval for its Duchenne Muscular Dystrophy Drug

    NORTHBROOK, Ill.–(BUSINESS WIRE)–Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD), the most common and …

March, 2016